Son Truong Nguyen

Rani Therapeutics (United States)

Papers

4

Total Citations

8

H-Index

2

About

Son Truong Nguyen is a pioneering researcher in oral biologic drug delivery, with a focus on developing robotic pill platforms that transform the administration of large-molecule therapeutics. His major contributions center on demonstrating that an orally ingested robotic pill can safely and reliably deliver complex biologics—such as the human parathyroid hormone analog teriparatide, an ustekinumab biosimilar, and a follicle-stimulating hormone biosimilar—with high bioavailability in healthy human volunteers. In Phase 1 studies (2023–2024), Nguyen and his team showed that this platform achieves pharmacokinetic and pharmacodynamic profiles comparable to subcutaneous injection, offering a needle-free alternative for chronic conditions like osteoporosis and autoimmune diseases. Each of his most-cited papers has garnered 2 citations, reflecting early but significant interest from the scientific community. Notably, his work on patient preference for a once-daily FSH biosimilar via robotic pill addresses a critical unmet need in reproductive health. Nguyen’s research, conducted at Rani Therapeutics, represents a paradigm shift in drug delivery, potentially improving adherence and quality of life for millions of patients requiring frequent injections.

Research Focus

Key Achievements

2
H-Index
4
Papers
8
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
SAT235 An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study
2 citations · 2023
📈 Most Prolific Year: 2023 (3 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Rani Therapeutics (United States)

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago